Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BioLineRx Ltd. AGM Information 2021

Oct 27, 2021

6692_ffr_2021-10-27_a9b6cadd-736f-47b1-bbed-17e98579c67e.zip

AGM Information

Open in viewer

Opens in your device viewer

6-K 1 zk2126692.htm 6-K Licensed to: Z-K GLOBAL Document created using EDGARfilings PROfile 7.6.0.0 Copyright 1995 - 2021 Broadridge

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2021

Commission file number: 001-35223


BioLineRx Ltd.

(Translation of registrant’s name into English)


2 HaMa’ayan Street Modi’in 7177871, Israel

(Address of Principal Executive Offices)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

The Registrant announces that it will hold the 2021 Annual General Meeting of Shareholders on December 2, 2021 at 3:00 p.m. (Israel time) at the Registrant’s office, 2 HaMa’ayan Street, Modi’in, Israel. Attached hereto as Exhibit 1 , Exhibit 2 and Exhibit 3 , are, respectively, the Notice of Annual General Meeting and Proxy Statement, and Form of Proxy Card and Form of Voting Instruction Card for American Depositary Share holders.

This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioLineRx Ltd.
By: /s/ Philip Serlin
Philip Serlin
Chief Executive Officer

Dated: October 27, 2021